Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shanghai Pharma Bumps Size of Hong Kong IPO by 50%

publication date: Apr 1, 2011
Shanghai Pharmaceuticals Holding, one of China's two biggest drug distribution companies, is planning to increase the size of its massive Hong Kong IPO by as much as 50%. Originally the company planned to raise $1.2 billion. Now it is proposing to expand the offering to $1.5 billion or $1.8 billion. The price per share appears to be unchanged from the 17.6 RMB specified in the first reports from last September. Apparently, the company will offer a bigger stake in the company than the 25% of capitalization originally proposed. More details....

Stock Symbol: (SHA: 601607)     Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital